home / stock / bmea / bmea quote
Last: | $11.57 |
---|---|
Change Percent: | 0.19% |
Open: | $10.72 |
Close: | $11.57 |
High: | $12.08 |
Low: | $10.6 |
Volume: | 1,116,871 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$11.57 | $10.72 | $11.57 | $12.08 | $10.6 | 1,116,871 | 05-01-2024 |
$10.74 | $10.66 | $10.74 | $11.125 | $10.56 | 589,833 | 04-30-2024 |
$10.75 | $10.86 | $10.75 | $11.16 | $10.615 | 512,171 | 04-29-2024 |
$10.78 | $10.57 | $10.78 | $10.9 | $10.39 | 583,288 | 04-26-2024 |
$10.47 | $10.53 | $10.47 | $10.55 | $10.26 | 501,987 | 04-25-2024 |
$10.77 | $11 | $10.77 | $11.24 | $10.445 | 752,634 | 04-24-2024 |
$10.98 | $10.79 | $10.98 | $11.39 | $10.72 | 685,328 | 04-23-2024 |
$10.83 | $11.01 | $10.83 | $11.28 | $10.808 | 603,210 | 04-22-2024 |
$10.85 | $11.03 | $10.85 | $11.545 | $10.22 | 1,318,800 | 04-19-2024 |
$11.16 | $11.41 | $11.16 | $11.87 | $10.95 | 1,671,352 | 04-18-2024 |
$11.5 | $12.09 | $11.5 | $12.1 | $11.4401 | 802,858 | 04-17-2024 |
$11.95 | $12.4 | $11.95 | $12.58 | $11.79 | 615,837 | 04-16-2024 |
$12.51 | $12.88 | $12.51 | $13.37 | $12.11 | 712,858 | 04-15-2024 |
$12.98 | $13.23 | $12.98 | $13.66 | $12.64 | 1,031,628 | 04-12-2024 |
$13.28 | $12.82 | $13.28 | $13.43 | $12.56 | 786,838 | 04-11-2024 |
$12.76 | $12.31 | $12.76 | $12.88 | $12.3 | 791,842 | 04-10-2024 |
$12.8 | $12.51 | $12.8 | $12.865 | $12.2 | 858,002 | 04-09-2024 |
$12.51 | $12.77 | $12.51 | $12.9835 | $12.42 | 601,199 | 04-08-2024 |
$12.73 | $12.61 | $12.73 | $13.28 | $12.01 | 1,218,733 | 04-05-2024 |
$12.605 | $14.03 | $12.605 | $14.43 | $12.52 | 1,250,642 | 04-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Biomea Fusion Inc. Company Name:
BMEA Stock Symbol:
NASDAQ Market:
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically d...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of be...
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. After just a 4-week treatment period in type 2 diabetes patients, who had previ...